Membranous nephropathy and cancer in the era of PLA 2 R testing

Abstract

Membranous nephropathy has historically been associated with a higher risk of malignancy compared to the general population. Following a membranous nephropathy diagnosis, physicians screen patients for underlying cancers at the time of and up to several years following the diagnosis. The discovery of phospholipase A₂ receptor (PLA₂R) as a major antigen in primary membranous nephropathy may be changing how we think about the association between membranous nephropathy and cancer. PLA₂R was found to be present in 72% of cases of idiopathic membranous nephropathy with very few PLA₂R patients having cancer. Following PLA₂R discovery, thrombospondin type-1 domain-containing 7A (THSD7A) was discovered. This antigen, in contrast to PLA₂R, may be more strongly associated with cancer. This review will evaluate the associations between these antigens and cancer, as well as propose an algorithm on cancer screening in the era of antibody testing.

Keywords

Cancer membranous nephropathy

Get full access to this article

View all access options for this article.

References

Deegens

Wetzels

JF.

Membranous nephropathy in the older adult: epidemiology, diagnosis and management. Drugs Aging 2007; 24(9): 717–732.

Glassock

RJ.

The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. Am J Kidney Dis 2010; 56(1): 157–167.

Ponticelli

Glassock

RJ.

Glomerular diseases: membranous nephropathy—a modern view. Clin J Am Soc Nephrol 2014; 9(3): 609–616.

Lee

Yamauchi

Hopper

Jr.

The association of cancer and the nephrotic syndrome. Ann Intern Med 1966; 64(1): 41–51.

Lefaucheur

Stengel

Nochy

et al . Membranous nephropathy and cancer: epidemiologic evidence and determinants of high-risk cancer association. Kidney Int 2006; 70(8): 1510–1517.

Beck

Jr Bonegio

Lambeau

et al . M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. New Engl J Med 2009; 361(1): 11–21.

Hofstra

Beck

Jr Beck

et al . Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011; 6: 1286–1291.

Kaplan

Klassen

Gault

MH.

Glomerular injury in patients with neoplasia. Annu Rev Med 1976; 27: 117–125.

Matsuura

Sakurai

Arima

Nephrotic syndrome due to membranous nephropathy associated with metastatic prostate cancer: rapid remission after initial endocrine therapy. Nephron 2000; 84(1): 75–78.

10.

Ashman

Steele

Sheaff

et al . Membranous nephropathy resolving with treatment of bronchial carcinoid tumor. Am J Kidney Dis 2000; 36(3): E15.

11.

Yahata

Kawanishi

Okabe

et al . Membranous glomerulonephritis with nephrotic syndrome associated with chronic lymphocytic leukemia. Am J Nephrol 2000; 20(5): 402–407.

12.

Yamauchi

Linsey

Biava

et al . Cure of membranous nephropathy after resection of carcinoma. Arch Intern Med 1985; 145(11): 2061–2063.

13.

Tan

Chuah

et al . A case of juxtaglomerular cell tumor associated with membranous glomerulonephritis. Ann Diagn Pathol 2003; 7(5): 314–320.

14.

Leeaphorn

Kue-A-Pai

Thamcharoen

et al . Prevalence of cancer in membranous nephropathy: a systematic review and meta-analysis of observational studies. Am J Nephrol 2014; 40(1): 29–35.

15.

Timmermans

Ayalon

van Paassen

et al . Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy. Am J Kidney Dis 2013; 62(6): 1223–1225.

16.

Birkeland

Storm

HH.

Glomerulonephritis and malignancy: a population-based analysis. Kidney Int 2003; 63(2): 716–721.

17.

Bjorneklett

Vikse

Svarstad

et al . Long-term risk of cancer in membranous nephropathy patients. Am J Kidney Dis 2007; 50(3): 396–403.

18.

Cantrell

EG.

Nephrotic syndrome cured by removal of gastric carcinoma. Br Med J 1969; 2(5659): 739–740.

19.

Takane

Midorikawa

Yamazaki

et al . Gastrointestinal stromal tumor with nephrotic syndrome as a paraneoplastic syndrome: a case report. J Med Case Rep 2014; 8: 108.

20.

Forgy

Ewing

Flaningam

Two paraneoplastic syndromes in a patient with ovarian cancer: nephrotic syndrome and paraneoplastic cerebellar degeneration. Gynecol Oncol 2001; 80(1): 96–98.

21.

Ito

Akimoto

Nakazawa

et al . A case of cervical cancer-related membranous nephropathy treated with radiation therapy. Intern Med 2011; 50(1): 47–51.

22.

Shikata

Hayashi

Yamazaki

et al . Effectiveness of radiation therapy in nephrotic syndrome associated with advanced lung cancer. Nephron 1999; 83(2): 160–164.

23.

Ohtani

Wakui

Komatsuda

et al . Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. Nephrol Dial Transplant 2004; 19(3): 574–579.

24.

Liu

et al . Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy. Nephrol Dial Transplant 2012; 27(5): 1931–1937.

25.

Gupta

Fattah

Ayalon

et al . Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation. Clin Transplant 2016; 30(4): 461–469.

26.

Debiec

Guigonis

Mougenot

et al . Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 2002; 346(26): 2053–2060.

27.

Debiec

Nauta

Coulet

et al . Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet 2004; 364(9441): 1252–1259.

28.

Vivarelli

Emma

Pelle

et al . Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies. Kidney Int 2015; 87(3): 602–609.

29.

Lonnbro-Widgren

Ebefors

Molne

et al . Glomerular IgG subclasses in idiopathic and malignancy-associated membranous nephropathy. Clin Kidney J 2015; 8(4): 433–439.

30.

Hoxha

Kneissler

Stege

et al . Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int 2012; 82(7): 797–804.

31.

Hofstra

Debiec

Short

et al . Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 2012; 23(10): 1735–1743.

32.

Ong

Silvestrini

Chapman

et al . Validation of a phospholipase A2 receptor antibody ELISA in an Australian cohort with membranous glomerulonephritis. Pathology 2016; 48(3): 242–246.

33.

Hill

McRae

Dwyer

KM.

PLA2R and membranous nephropathy: a 3 year prospective Australian study. Nephrology 2016; 21(5): 397–403.

34.

Qin

Beck

Jr Zeng

et al . Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 2011; 22(6): 1137–1143.

35.

Yang

Kim

et al . Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy. PLoS ONE 2013; 8(4): e62151.

36.

Hihara

Iyoda

Tachibana

et al . Anti-phospholipase A2 receptor (PLA2R) antibody and glomerular PLA2R expression in Japanese patients with membranous nephropathy. PLoS ONE 2016; 11(6): e0158154.

37.

Akiyama

Imai

et al . Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy. Clin Exp Nephrol 2015; 19(4): 653–660.

38.

Segarra-Medrano

Jatem-Escalante

Quiles-Perez

et al . Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy. Nefrologia 2014; 34(3): 353–359.

39.

Hoxha

Beck

Jr Wiech

et al . An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7a-specific antibodies in membranous nephropathy. J Am Soc Nephrol 2017; 28: 520–531.

40.

Kim

et al . Induction of cellular senescence by secretory phospholipase A2 in human dermal fibroblasts through an ROS-mediated p53 pathway. J Gerontol A Biol Sci Med Sci 2009; 64(3): 351–362.

41.

Augert

Payre

de Launoit

et al . The M-type receptor PLA2R regulates senescence through the p53 pathway. EMBO Rep 2009; 10(3): 271–277.

42.

Valentin

Singer

Ghomashchi

et al . Cloning and recombinant expression of human group IIF-secreted phospholipase A(2). Biochem Biophys Res Commun 2000; 279(1): 223–228.

43.

Tomas

Beck

Jr Meyer-Schwesinger

et al . Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014; 371(24): 2277–2287.

44.

Hoxha

Wiech

Stahl

et al . A mechanism for cancer-associated membranous nephropathy. N Engl J Med 2016; 374(20): 1995–1996.

45.

Otani

Shimojo

Shiozawa

et al . Renal involvement in bone marrow transplantation. Nephrology 2005; 10(5): 530–536.

46.

Hiesse

Goldschmidt

Santelli

et al . Membranous nephropathy in a bone marrow transplant recipient. Am J Kidney Dis 1988; 11(2): 188–191.

47.

Chang

Hingorani

Kowalewska

et al . Spectrum of renal pathology in hematopoietic cell transplantation: a series of 20 patients and review of the literature. Clin J Am Soc Nephrol 2007; 2(5): 1014–1023.

48.

Terrier

Delmas

Hummel

et al . Post-allogeneic haematopoietic stem cell transplantation membranous nephropathy: clinical presentation, outcome and pathogenic aspects. Nephrol Dial Transplant 2007; 22(5): 1369–1376.

49.

Byrne-Dugan

Collins

Lam

et al . Membranous nephropathy as a manifestation of graft-versus-host disease: association with HLA antigen typing, phospholipase A2 receptor, and C4d. Am J Kidney Dis 2014; 64(6): 987–993.

50.

Hiramatsu

Ubara

Sawa

et al . Clinicopathological analysis of allogeneic hematopoietic stem cell transplantation-related membranous glomerulonephritis. Hum Pathol 2016; 50: 187–194.

51.

Abudayyeh

Truong

Beck

Jr , . Membranous nephropathy in autologous hematopoietic stem cell transplant: autologous graft-versus-host disease or autoimmunity induction? Clin Kidney J 2015; 8(4): 440–444.